4-羟基吡咯并[1,2-B]哒嗪-2(1H)-酮 | 270902-36-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-羟基吡咯并[1,2-B]哒嗪-2(1H)-酮
• 中文别名: 4-羟基-吡咯并[1,2-b]吡嗪-2(1H)-酮
• 英文名称: 4-Hydroxypyrrolo[1,2-b]pyridazin-2(1H)-one
• 英文别名: 4-hydroxy-1H-pyrrolo[1,2-b]pyridazin-2-one
• CAS: 270902-36-8
• 化学式: C₇H₆N₂O₂
• mdl: MFCD09263870
• 分子量: 150.13
• InChiKey: RVCPUGGZZIWUCR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933990090

文献信息

• COMPOUNDS AND METHODS FOR THEIR USE
  申请人：Deng Shaojiang

  公开号：US20100047367A1

  公开（公告）日：2010-02-25

  The present invention relates to novel compounds capable of modulating the stability and/or activity of hypoxia inducible factor (HIF) by inhibiting the activity of at least one HIF hydroxylase enzyme.

  本发明涉及一种能够通过抑制至少一种HIF羟基化酶的活性来调节缺氧诱导因子（HIF）的稳定性和/或活性的新化合物。
• PHOTOREACTIVE REGULATOR OF GLUTAMATE RECEPTOR FUNCTION AND METHODS OF USE THEREOF
  申请人：Trauner Dirk

  公开号：US20090181454A1

  公开（公告）日：2009-07-16

  The present invention provides a synthetic regulator of glutamate receptor function, which regulator is a light-sensitive (photoreactive) regulator. The present invention further provides a light-regulated glutamate receptor that includes a subject synthetic regulator non-covalently associated with the glutamate receptor. Also provided are cells and membranes comprising a subject light-regulated glutamate receptor. The present invention further provides methods of modulating glutamate receptor function, involving use of light. The present invention further provides methods of identifying agents that modulate glutamate receptor function.

  本发明提供了一种合成的谷氨酸受体功能调节剂，该调节剂是一种光敏感（光反应性）调节剂。本发明还提供了一种光调节的谷氨酸受体，其中包括与谷氨酸受体非共价结合的主体合成调节剂。还提供了包括主体光调节谷氨酸受体的细胞和膜。本发明还提供了使用光调节谷氨酸受体的调节谷氨酸受体功能的方法。本发明还提供了识别调节谷氨酸受体功能的药剂的方法。
• New use of glutamate antagonists for the treatment of cancer
  申请人：Ikonomidou, Hrissanthi

  公开号：EP1002535A1

  公开（公告）日：2000-05-24

  New therapies can be devised based upon a demonstration of the role of glutamate in the pathogenesis of cancer. Inhibitors of the interaction of glutamate with the AMPA, kainate, or NMDA receptor complexes are likely to be useful in treating cancer and can be formulated as pharmaceutical compositions. They can be identified by appropriate screens.

  根据谷氨酸在癌症发病机制中的作用，可以设计出新的疗法。谷氨酸与 AMPA、kainate 或 NMDA 受体复合物相互作用的抑制剂可能有助于治疗癌症，并可配制成药物组合物。它们可以通过适当的筛选来确定。
• Treatment of glial tumors with glutamate antagonists
  申请人：——

  公开号：US20030050224A1

  公开（公告）日：2003-03-13

  The present invention relates to a method of treating glial tumors in a subject, which includes providing a glutamate antagonist or a NMDA receptor antagonist and administering the glutamate antagonist or NMDA receptor antagonist to a subject with a glial tumor of the brain or spinal cord under conditions effective to treat the glial tumor.

  本发明涉及一种治疗受试者神经胶质瘤的方法，该方法包括提供谷氨酸拮抗剂或NMDA受体拮抗剂，并在有效治疗神经胶质瘤的条件下将谷氨酸拮抗剂或NMDA受体拮抗剂施用于患有脑或脊髓神经胶质瘤的受试者。
• Use of glutamate antagonists for the treatment of cancer
  申请人：Ikonomidou Hrissanthi

  公开号：US20050054619A1

  公开（公告）日：2005-03-10

  Disclosed are methods for treating cancer by administering an inhibitor of the interaction of glutamate with the KA receptor complex.

  所公开的是通过施用谷氨酸与 KA 受体复合物相互作用的抑制剂来治疗癌症的方法。